EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Intravitreal Anti-Vascular Endothelial Growth Factor Therapies for Retinal Disorders

Abraham Hang, Samuel Feldman, Aana P Amin, Jorge A Rivas Ochoa, Susanna S Park iD

Pharmaceuticals · 11.08.2023 · 16 (8) · 1140

DOI: 10.3390/ph16081140 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 11.08.2023. Verfasst von Abraham Hang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology & Vision Science, Ernest E. Tschannen Eye Institute, University of California Davis Eye Center, 4860 Y Street, Sacramento…. Die Arbeit wurde bisher 77-mal zitiert (Crossref) und nennt 142 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Barbara A. & Alan M. Roth, MD Endowed Chair for Discovery, Education and Patient Care in Vision Science from University of California Davis, Barbara A. & Alan M. Roth, MD Endowed Chair for Discovery, Education and Patient Care in Vision Science from the University of California Davis (SSP).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vascular endothelial growth factors (VEGFs) are key mediator of retinal and choroidal neovascularization as well as retinal vascular leakage leading to macular edema. As such, VEGF plays an important role in mediating visually significant complications associated with common retinal disorders such as diabetic retinopathy, retinal vein occlusion, and age-related macular degeneration. Various drugs that inhibit vascular endothelial growth factors (anti-VEGF therapies) have been developed to minimize vision loss associated with these disorders. These drugs are injected into the vitreous cavity in a clinic setting at regular intervals. This article provides an overview of the various anti-VEGF drugs used in ophthalmology and the common retinal conditions that benefit from this therapy.

Schlagwörter

Stichwörter der Autor:innen

anti-VEGF therapychoroidal neovascularizationintravitreal therapyretinal diseaseretinal neovascularizationvascular endothelial growth factors (VEGFs)

Autor:innen und Institutionen

  • Department of Ophthalmology & Vision Science, Ernest E. Tschannen Eye Institute, University of California Davis Eye Center, 4860 Y Street, Sacramento, CA 95817, USA.
  • School of Medicine, University of California Davis, Sacramento, CA 95817, USA.

ORCID-Profile: Susanna S Park

Förderung

  • Barbara A. & Alan M. Roth, MD Endowed Chair for Discovery, Education and Patient Care in Vision Science from University of California Davis
  • Barbara A. & Alan M. Roth, MD Endowed Chair for Discovery, Education and Patient Care in Vision Science from the University of California Davis (SSP)

Zitieren

APA

Hang, A., Feldman, S., Amin, A. P., Ochoa, J. A. R., & Park, S. S. (2023). Intravitreal Anti-Vascular Endothelial Growth Factor Therapies for Retinal Disorders. Pharmaceuticals, 16(8), 1140. https://doi.org/10.3390/ph16081140

Vancouver

Hang A, Feldman S, Amin AP, Ochoa JAR, Park SS. Intravitreal Anti-Vascular Endothelial Growth Factor Therapies for Retinal Disorders. Pharmaceuticals. 2023;16(8):1140. doi:10.3390/ph16081140

BibTeX
@article{Hang2023,
  author = {Hang, Abraham and Feldman, Samuel and Amin, Aana P and Ochoa, Jorge A Rivas and Park, Susanna S},
  title = {Intravitreal Anti-Vascular Endothelial Growth Factor Therapies for Retinal Disorders},
  journal = {Pharmaceuticals},
  year = {2023},
  volume = {16},
  number = {8},
  pages = {1140},
  doi = {10.3390/ph16081140}
}
Kostenlos starten →